Included in the formulation
АТХ:R.05.D.B Other antitussives
R.05.D.B.27 Ledvropropizin
Pharmacodynamics:Antitussive, mainly peripheral action. Reduces the sensitivity of the respiratory tract receptors by inhibiting the release of histamine and neuropeptides. Reduces the intensity and frequency of cough.
Pharmacokinetics:Not studied.
Indications:It is used for symptomatic treatment of dry cough, including allergic genesis.
X.J10-J18.J15.9 Bacterial pneumonia, unspecified
X.J40-J47.J47 Bronchoectasia
X.J40-J47.J42 Chronic bronchitis, unspecified
X.J20-J22.J20 Acute bronchitis
X.J10-J18.J18.0 Bronchopneumonia, unspecified
X.J40-J47.J43.9 Emphysema (lung) (pulmonary)
X.J40-J47.J45 Asthma
XVIII.R00-R09.R05 Cough
Contraindications:Reduction of mucociliary function, increased sputum separation, liver failure, individual intolerance.
Carefully:Hepatic insufficiency of mild and moderate degree, severe renal failure.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Use in children
From 2 years of age to 12 years, 1 mg / kg 3 times a day.
Adults
Inside for 60 mg 3 times a day at intervals of 6 hours.
The highest daily dose: 180 mg.
The highest single dose: 60 mg.
Side effects:Central and peripheral nervous system: opacities, drowsiness, fatigue, headache, dizziness.
Digestive system: heartburn, nausea, diarrhea.
Allergic reactions.
Overdose:Symptoms: increased side effects, vomiting, loss of consciousness.
Treatment: symptomatic.
Interaction:Simultaneous use with sedatives increases the depressing effect on the central nervous system.
Special instructions:Use with caution in patients whose professional activities require concentration of attention.